DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Jakafi (Ruxolitinib) - Current Clinical Trials

 
 



Jakafi Related Clinical Trials

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) [Recruiting]

Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML) [Recruiting]

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) [Recruiting]

Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II [Recruiting]

Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [Recruiting]

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Recruiting]

Study of Ruxolitinib in Colorectal Cancer Patients [Recruiting]

Phase l/II Study of Ruxolitinib for Acute Leukemia [Active, not recruiting]

Ruxolitinib in Combination With Autotransplant [Recruiting]

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis [Recruiting]

A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis [Completed]

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) [Completed]

Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer [Recruiting]

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea [Recruiting]

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer [Recruiting]

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients [Completed]

Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia [Active, not recruiting]

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis [Active, not recruiting]

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis [Completed]

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Active, not recruiting]

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib [Recruiting]

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) [Recruiting]

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia [Recruiting]

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis [Suspended]

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis [Not yet recruiting]

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer [Terminated]

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma [Completed]

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca [Recruiting]

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial [Active, not recruiting]

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. [Active, not recruiting]

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer [Recruiting]

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib [Recruiting]

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients [Recruiting]

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) [Recruiting]

A Study of Ruxolitinib in Pancreatic Cancer Patients [Recruiting]

Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma [Recruiting]

An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata [Active, not recruiting]

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis [Recruiting]

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients [Recruiting]

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis [Active, not recruiting]

Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm [Recruiting]

INCB018424 in Patients With Advanced Hematologic Malignancies [Active, not recruiting]

Study of Ruxolitinib in Pancreatic Cancer Patients [Active, not recruiting]

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF [Recruiting]

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML [Recruiting]

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis [Recruiting]

A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis [Completed]

Ruxolitinib In GvHD [Not yet recruiting]

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older [Recruiting]

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia [Recruiting]

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome [Not yet recruiting]

Ruxolitinib in Patients With Breast Cancer [Active, not recruiting]

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. [Recruiting]

Ruxolitinib for Chuvash Polycythemia [Available]

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia [Recruiting]

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) [Recruiting]

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors [Active, not recruiting]

Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease [Recruiting]

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis [Recruiting]

Ruxolitinib for Adult T-Cell Leukemia [Recruiting]

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis [Completed]

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults [Not yet recruiting]

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease [Completed]

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma [Recruiting]

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases. [Recruiting]

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis [Completed]

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis [Completed]

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) [Active, not recruiting]

Ruxolitinib in Estrogen Receptor Positive Breast Cancer [Recruiting]

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC) [Not yet recruiting]

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis [Completed]

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis [Recruiting]

CINC424A2X01B Rollover Protocol [Recruiting]

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial [Active, not recruiting]

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma [Not yet recruiting]

A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis [Recruiting]

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF [Active, not recruiting]

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma [Active, not recruiting]

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Completed]

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. [Recruiting]

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF [Recruiting]

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) [Completed]

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy [Recruiting]

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF [Recruiting]

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms [Active, not recruiting]

PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017